Yogen Kanthi
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| Yogen Kanthi | |
|---|---|
 File:NHLBI - Dr. Yogen Kanthi.jpg | |
| Born | 1979 |
| 🏫 Education | Ohio State University College of Medicine University of Michigan Xavier University |
| 💼 Occupation | |
| Twitter= | |
Yogen Kanthi (born 1979) is an American cardiologist and vascular medicine specialist at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, Maryland, where he studies the role of immunity and inflammation in the development of vascular diseases. He is a Lasker Clinical Research Scholar Awardee[1] at the National Institutes of Health (NIH) and is presently the head of the Laboratory of Vascular Thrombosis and Inflammation at NHLBI, Lasker Scholar and a member of the Distinguished Scholar Program[2] at NIH.
Education and early career[edit]
Yogen Kanthi completed medical school at the Ohio State University College of Medicine, his residency and chief medical residency in internal medicine at University Hospitals Case Medical Center in 2009. He completed advanced fellowships in cardiology, vascular medicine, and a post-doctoral fellowship in vascular biology with David Pinsky at the University of Michigan. He has been a faculty member at the University of Michigan since 2014 and helps to direct its Vascular Medicine Fellowship Program.[3] Kanthi was elected to the Board of Trustees of the Society for Vascular Medicine in 2021.[4]
Kanthi's initial research focused on the role of purinergic regulation by bio-mechanical forces and performed studies demonstrating that the ectonucleotidase CD39/ENTPD1 could protect blood vessels against atherosclerosis.[5] After treating a series of young patients in his clinic with unexplained blood clots, he focused his research program to study the inflammatory causes of thrombosis. In 2019, he extended his findings of purinergic signaling in blood vessels to demonstrate that an inflammatory cytokine, interleukin 1 beta can cause venous thrombosis, and how CD39/ENTPD1 can prevent neutrophils from undergoing an inflammatory form of cell death that releases neutrophil extracellular traps.[6][7]
In 2020, the Albert and Mary Lasker Foundation and the NIH named Kanthi a Lasker Investigator,[1] and recruited him from the University of Michigan to start a Vascular Medicine Translational Research Program at the NIH focused on the role of inflammation in thrombotic diseases.
Current work and achievements[edit]
Following the onset of the pandemic, Kanthi and University of Michigan rheumatologist, Jason S. Knight, extended their prior collaborations on adenosine signaling in vascular and autoimmune disease[8] to understand the causes of severe COVID-19.[9][10] Together, disocvered the role of neutrophil extracellular traps in patients with COVID-19.[11] Although controversial at the time, their work has been replicated by many groups across the world. They also discovered that patients with severe COVID-19 infection have dysregulated production of prothrombotic autoantibodies, similar to another thromboinflammatory disorder antiphospholipid syndrome,[12] now considered a landmark discovery about the pathobiology of blood clotting in COVID-19.[13] They demonstrated that autoantibodies from patients with severe COVID contribute to inflammation in neutrophils and endothelial cells.[14] They went on to identify a novel biomarker calprotectin that predicts the risk of respiratory failure in patients hospitalized with COVID-19.[15] Altogether, his contributions to understanding the thrombotic and inflammatory processes that affect patients with COVID-19 have received widespread press coverage and have directly informed multiple clinical trials.[16][17][18][19][20] Kanthi has advocated for high quality clinical trials in COVID-19 to test repurposed drugs that are accessible and available to developing nations.[21][22]
Kanthi's ongoing work is focused on unraveling the inflammatory causes of thrombosis to develop new treatments for patients with vascular disease.[23]
Honors and awards[edit]
Notable publications[edit]
- Kanthi Y, Hyman MC...Pinsky DJ. Flow-dependent Expression of Ectonucleotidase tri(di)phosphohydrolase-1 and Suppression of Atherosclerosis. Journal of Clinical Investigation. 2015, Aug 3. doi: 10.1172/JCI79514. PubMed PMID 26121751.[5]
- Yadav V,...Kanthi Y. ENTPD-1 Disrupts Inflammasome IL-1 beta –driven Venous Thrombosis. Journal of Clinical Investigation. 2019, Apr 16. doi: 10.1172/JCI124804. PubMed PMID 3099798.[6]
- Zuo Y,... Kanthi Y*, Knight JS* *equal contributions. Prothrombotic Autoantibodies in Serum from Patients Hospitalized with COVID-19. Science Translational Medicine, 2021, Oct 30. doi: 10.1126//scitranslmed.abd3876. PubMed PMID 3313330519.[12]
- Zuo Y,... Kanthi Y*, Knight JS* *equal contributions. Neutrophil Extracellular Traps in COVID-19. JCI Insight, 2020, April 23. doi: 10.1171/jci.insight.138999. PubMed PMID 32329756.[11]
- Kanthi Y, Knight JS, Zuo Y, Pinsky DJ. New (re)Purpose for an Old Drug: Purinergic Modulation may Extinguish the COVID-19 Thromboinflammatory Firestorm. JCI Insight, 2020, Jul 23. doi: 10.1172/jci.insight.140971. PubMed PMID 32530438.[24]
- Colling ME and Kanthi Y. COVID-19 – associated coagulopathy: An Exploration of Mechanisms. Vascular Medicine Journal, 2020, Jun 19. doi: 10.1177/1358863X20932640. PubMed PMID 32558620.[25]
- Colling M, Tourdot BE and Kanthi Y. Inflammation, Infection and Venous Thromboembolism. Circulation Research, 2021, Jun 11. doi: 10.1161/CIRCRESAHA.121.318225. PubMed PMID 34110909.[26]
References[edit]
- ↑ 1.0 1.1 "Lasker Clinical Research Scholars".
- ↑ "Principal Investigators". NIH Intramural Research Program.
- ↑ "University of Michigan Vascular Medicine". 6 October 2020.
- ↑ "Board of Trustees | Society for Vascular Medicine". www.vascularmed.org. Retrieved 2022-02-03.
- ↑ 5.0 5.1 Kanthi, Y*; Hyman, MC*; Liao, H; Baek, AE; Visovatti, SH; Sutton, NR; Goonewardena, SN; Neral, MK; Jo, H; Pinsky, DJ (2015). "Flow-dependent Expression of Ectonucleotidase tri(di)phosphohydrolase-1 and Suppression of Atherosclerosis". Journal of Clinical Investigation. 125 (8): 3027–3036. doi:10.1172/JCI79514. PMC 4563746. PMID 26121751.
- ↑ 6.0 6.1 Yadav, V; Chi, L; Zhao, R; Tourdot, BE; Yalavarthi, S; Jacobs, BN; Banka, A; Liao, H; Koonse, S; Anyanwu, AC; Visovatti, SH; Holinstat, MA; Kahlenberg, JM; Knight, JS; Pinsky, DJ; Kanthi, Y (2019). "ENTPD-1 Disrupts Inflammasome IL-1 beta –driven Venous Thrombosis". Journal of Clinical Investigation. 127 (7): 1872–2877. doi:10.1172/JCI124804. PMC 6597243 Check
|pmc=value (help). PMID 3099798. - ↑ Anyanwu, AC*; Kanthi, Y*; Fukase, K; Liao, H; Mimura, T; Desch, KC; Gruca, M; Kaskar, S; Sheikh-Aden, H; Chi, L; Zhao, R; Yadav, V; Wakefield, TW; Hyman, MC; Pinsky, DJ (2019). "Tuning the Thromboinflammatory Response to Venous Flow Interruption by the Ectonucleotidase CD39". Arteriosclerosis, Thrombosis, and Vascular Biology. 39 (4): e118–129. doi:10.1161/ATVBAHA.119.312407. PMC 6467508. PMID 30816804.
- ↑ Ali, RA*; Gandhi, AA*; Meng, H; Yalavarthi, S; Vreede, AP; Estes, SK; Palmar, OR; Bockenstedt, PL; Pinsky, DJ; Greve, JM; Diaz, JA; Kanthi, Y; Knight, JS (2019). "Adenosine Receptor Agonism Protects Against NETosis and Thrombosis in Antiphospholipid Syndrome". Nature Communications. 10 (1): 1916. Bibcode:2019NatCo..10.1916A. doi:10.1038/s41467-019-09801-x. PMC 6478874. PMID 31015489.
- ↑ "Frankel Cardiovascular Center COVID-19 Ignitor Award". www.medicine.umich.edu. 9 April 2020.
- ↑ "Institute supports first U-M based COVID study". A. Alfred Taubman Medical Research Institute. 2020-06-05. Retrieved 2022-02-03.
- ↑ 11.0 11.1 Zuo, Y; Yalavarthi, S; Shi, H; Gockman, K; Zuo, M; Madison, JA; Blair, C; Weber, A; Barnes, BJ; Egeblad, M; Woods, RJ; Kanthi, Y*; Knight, JS* (co-corresponding) (2020). "Neutrophil Extracellular Traps in COVID-19". Jci Insight. 5 (11): e138999. doi:10.1172/jci.insight.138999. PMC 7308057 Check
|pmc=value (help). PMID 32329756 Check|pmid=value (help). - ↑ 12.0 12.1 Zuo, Y; Estes, SK; Ali, RA; Gandhi, AA; Yalavarthi, S; Shi, H; Sule, G; Gockman, K; Madison, JA; Zuo, M; Yadav, V; Wang, J; Woodard, W; Lezak, SP; Lugogo, NL; Smith, SA; Morrissey, JH; Kanthi, Y*; Knight, JS* (co-corresponding) (2020). "Prothrombotic Autoantibodies in Serum from Patients Hospitalized with COVID-19". Science Translational Medicine. 12 (570): eabd3876. doi:10.1126/scitranslmed.abd3876. PMC 7724273 Check
|pmc=value (help). PMID 33139519 Check|pmid=value (help). - ↑ "How COVID-19 may trigger dangerous blood clots". Science News. 2020-11-02. Retrieved 2022-02-03.
- ↑ Shi, H; Zuo, Y; Navaz, S; Harbaugh, A; Hoy, C; Gandhi, AA; Sule, G; Yalavarthi, S; Gockman, K; Madison, JA; Wang, J; Zuo, M; Shi, Y; Maile, MD; Knight, JS*; Kanthi, Y* (co-corresponding) (2021). "Endothelial cell-Activating Antibodies in COVID-19". medRxiv: The Preprint Server for Health Sciences. doi:10.1101/2021.01.18.21250041. PMC 7836141 Check
|pmc=value (help). PMID 33501469 Check|pmid=value (help). - ↑ Shi, H; Zuo, Y; Yalavarthi, S; Gockman, K; Zuo, M; Madison, JA; Blair, C; Woodward, W; Lezak, SP; Lugogo, NL; Woods, RJ; Lood, C; Knight, JS*; Kanthi, Y* (co-corresponding) (2020). "Neutrophil Calprotectin Identifies Severe Pulmonary Disease in COVID-19". Journal of Leukocyte Biology. 109 (1): 67–72. doi:10.1002/JLB.3COVCRA0720-359R. PMC 7902293 Check
|pmc=value (help). PMID 32869342 Check|pmid=value (help). - ↑ "Spider-Man Immune Response May Promote Severe COVID-19". Scientific American.
- ↑ "Scientists Have Uncovered the Likely Cause of a Serious COVID-19 Symptom: Blood Clotting". TIME.
- ↑ "Clots, Strokes and Rashes. Is COVID-19 a Disease of the Blood Vessels?". NPR.
- ↑ "Novel autoantibody adds fuel to the COVID-19 'firesorm' of inflammation, blood clots". Science Daily.
- ↑ "New Target to Combat COVID-Related Thrombosis?". Medscape.
- ↑ "Cheap Generics Might Treat COVID-19 but Obstacles Abound". Medscape.
- ↑ Kanthi, Y; Knight, JS; Zuo, Y; Pinsky, DJ (2020). "New (re)Purpose for an Old Drug: Purinergic Modulation may Extinguish the COVID-19 Thromboinflammatory Firestorm". Jci Insight. 5 (14): e140971. doi:10.1172/jci.insight.140971. PMC 7453890 Check
|pmc=value (help). PMID 32530438 Check|pmid=value (help). - ↑ "National Thrombosis Week - Virtual Conference - 3rd - 9th May 2021 - Presented by Thrombosis UK #KnowThrombosis". nationalthrombosisweek.com. Retrieved 2022-02-03.
- ↑ Kanthi, Y; Knight, JS; Zuo, Y; Pinsky, DJ (2020). "New (re)Purpose for an Old Drug: Purinergic Modulation may Extinguish the COVID-19 Thromboinflammatory Firestorm". Jci Insight. 5 (14): e140971. doi:10.1172/jci.insight.140971. PMC 7453890 Check
|pmc=value (help). PMID 32530438 Check|pmid=value (help). - ↑ Colling, ME; Kanthi, Y (2020). "COVID-19 – associated coagulopathy: An Exploration of Mechanisms". Vascular Medicine. 25 (5): 471–478. doi:10.1177/1358863X20932640. PMC 7306998 Check
|pmc=value (help). PMID 32558620 Check|pmid=value (help). - ↑ Colling, ME; Tourdot, BE; Kanthi, Y (2021). "Inflammation, Infection and Venous Thromboembolism". Circulation Research. 128 (12): 2017–2036. doi:10.1161/CIRCRESAHA.121.318225. PMC 8202069 Check
|pmc=value (help). PMID 34110909 Check|pmid=value (help).
External links[edit]
This article "Yogen Kanthi" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Yogen Kanthi. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
